Godavari Biorefineries Secures Chinese Patent for Breakthrough Anti-Cancer Molecule

Godavari Biorefineries Limited, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company’s clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world’s most urgent health challenges.